Mobile Devices to Detect Early Pneumonitis in Stage III NSCLC Patients on Durvalumab.
Stopped early · Phase 4
Conditions studied: Unresectable Stage III NSCLC
In brief
A study of whether mobile devices can improve the detection of pulmonary AEs (including pneumonitis) in stage III NSCLC patients post-CRT, while on durvalumab.
Key facts
- Study ID
- NCT04381494
- Run by
- AstraZeneca
- People needed
- 40
- Starts
- 2020-04-27
- Expected to finish
- 2022-01-27
- Last updated by the study team
- 2023-06-22
Who can join
Age: 18 and older, up to 130. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Research Site — Atlanta, Georgia, United States
- Research Site — Santa Ana, California, United States
- Research Site — Westwood, Kansas, United States
- Research Site — Louisville, Kentucky, United States
- Research Site — Pontiac, Michigan, United States
- Research Site — New York, New York, United States
- Research Site — Cincinnati, Ohio, United States
- Research Site — Massillon, Ohio, United States
- Research Site — Knoxville, Tennessee, United States
- Research Site — San Antonio, Texas, United States
- Research Site — Lacey, Washington, United States
- Research Site — Tacoma, Washington, United States
- Research Site — Long Beach, California, United States
- Research Site — Englewood, Colorado, United States
- Research Site — Plainville, Connecticut, United States
- Research Site — Boca Raton, Florida, United States
- Research Site — Tallahassee, Florida, United States
- Research Site — Tampa, Florida, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.